Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Luminal proteins and toxins refer to a diverse group of substances found within the gastrointestinal tract that contribute to various disease states through local irritation or systemic absorption. This category encompasses bacterial toxins (such as Clostridioides difficile toxins A and B), dietary antigens (such as gluten), and metabolic waste products (such as uremic toxins and bile acids). These substances are targeted by non-absorbed therapeutic agents, primarily oral adsorbents and sequestrants, which act by physically binding or sequestering these molecules to prevent their pathological effects. For example, drugs like sevelamer and AST-120 are used to manage hyperphosphatemia and uremia by binding phosphate and uremic toxins, respectively, while others like cholestyramine can neutralize bacterial toxins. Because these agents remain in the gut lumen and are not absorbed into the bloodstream, they offer a unique therapeutic approach but may also lead to non-specific binding of nutrients and other medications.
Adsorption, sequestration, or enzymatic degradation of proteins and toxins within the gastrointestinal lumen.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Luminal proteins and toxins.